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Abstract
We previously reported that deferoxamine, an iron chelating agent, induced p53 and cell accumulation in the G1 phase of
ML-1 cells in the same way as the DNA damaging agent, etoposide. Etoposide treatment increased expression of the p21
gene, a cyclin kinase inhibitor, at both the mRNA and protein levels. However, deferoxamine treatment only increased the
p21 mRNA level without the appearance of a detectable protein product. A substrate for cyclin kinase, pRB, was
unphosphorylated by etoposide treatment, but remained unaffected by deferoxamine, indicating that p21 was functional
after etoposide, but not after deferoxamine treatment. Therefore, in the present study, we investigated the involvement of the
ubiquitin proteasome pathway in post-transcriptional regulation of p21. By the addition of lactacystin, a proteasome
inhibitor, to deferoxamine treatment, the level of unubiquitinated p21 protein product was similar to that induced by
etoposide treatment, and the ubiquitinated p21 bands became apparent. After etoposide treatment, the level of ubiquitinated
p21 was diminished and a high level of unubiquitinated p21 expression was observed. We concluded that (1) efficient
expression of p21 protein requires inhibition of the ubiquitin-proteasome pathway, and (2) DNA damage inhibits the
ubiquitination of p21. 0167-4889 / 98 / $ ^ see front matter ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cell cycle transition is regulated by the coordi-
nated expression of many components, such as p53,
cyclin, CDKs, and CDK inhibitors [1,2]. Expression
of the relevant genes is controlled by transcription,
mRNA stability, or protein stability.
A CDK inhibitor, p21, inhibits the cell cycle
through its interaction with cyclin-CDK complexes
[3,4]. Expression of p21 appears to be regulated by
both transcriptional and post-transcriptional mecha-
nisms. At the transcriptional level, p21 mRNA is
induced by wild-type p53 [5], and also induced inde-
pendently of p53 in several situations, including nor-
mal tissue development [6], cellular di¡erentiation [7^
9], the presence of DNA damaging agents [10^12],
TGF-L treatment [13,14], retinoic acid treatment
[15], vitamin D3 treatment [16] and interferon treat-
ment [17]. Post-transcriptional regulation of p21 ex-
pression has been demonstrated: stabilization of p21
mRNA during hematopoietic di¡erentiation [18] or
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after TNFK treatment [19], or okadaic acid-induced
p21 expression without mRNA stabilization [20].
The involvement of ubiquitin-proteasome degrada-
tion of several cell cycle-regulatory proteins, such as
cyclin [21], p27 [22], or p53 [23], has been reported.
Levels of wild-type p53 are quite low due to a short
protein half-life. However, p53 protein accumulates
after the treatment of cells with various DNA dam-
aging agents via di¡erent mechanisms, such as in-
creased translation [24] and protein stabilization
[25]. Maki and Howley demonstrated that UV irra-
diation of cells led to the stabilization of wild-type
p53 through the loss of p53 ubiquitination [26]. The
p53 function that induces apoptosis was accom-
plished with the stabilization and accumulation of
p53 protein after treatment with proteasome inhibi-
tor [27]. Recently, the regulation of p21 expression
by the ubiquitin-proteasome degradation pathway
was postulated after demonstrating in vivo ubiquiti-
nation [25,26,28].
We previously reported a cellular response to
treatment with deferoxamine B mesylate (DFO), an
iron-chelating agent, using a myelocytic leukemia cell
line, ML-1, which contains wild-type p53 [30,31]. It is
generally thought that DFO inhibits the iron-requir-
ing enzyme ribonucleotide reductase, thereby altering
the supply of deoxyribonucleotides and decreasing
DNA synthesis [29]. We observed the increase of
p53 protein followed its accumulation in the G1
phase after treatment of ML-1 cells with DFO
[30,31]. The accumulation of p53 protein by DFO
treatment was similar to that observed after treat-
ment with etoposide, a topoisomerase II inhibitor
[32], or cytosine arabinoside (AraC), an antimetabo-
lite [33]. Subsequently, p21 mRNA expression was
enhanced by these treatments, but increased p21 pro-
tein product was observed only in cells treated with
etoposide, and not in cells treated with DFO or
AraC, which do not cause DNA damage [31]. A
substrate of cyclin dependent kinase, pRB (retino-
blastoma protein), was unphosphorylated by etopo-
side treatment, but not a¡ected by DFO treatment
indicating that p21 was functional after etoposide
treatment, but not after DFO treatment [31]. These
¢ndings suggested that the expression of p21 is regu-
lated post-transcriptionally. In this study, we inves-
tigated the involvement of the ubiquitin-proteasome
degradation pathway in p21 post-transcriptional reg-
ulation by comparing ubiquitination after treatment
with DNA damaging and non-damaging agents.
2. Materials and methods
2.1. Cell culture and treatment
A myelocytic leukemia cell line, ML-1 cells, sup-
plied by the Health Science Research Resource Bank
(HSRRB), was cultured in RPMI 1640 containing
10% fetal calf serum. Deferoxamine B mesylate
(DFO, Mr 656.8) was obtained from Ciba-Geigy
(Basel, Switzerland). Etoposide, hydroxyurea, and
AraC were purchased from Sigma (USA). Lactacys-
tin was kindly provided by Dr. S. Omura of the
Kitasato Institute [34]. Etoposide and lactacystin
were dissolved in dimethyl sulfoxide (DMSO) at con-
centrations of 1U1031 M and 1U1032 M, respec-
tively. DFO, hydroxyurea and AraC were dissolved
in H2O at a concentration of 1U1031 M. Exponen-
tially growing ML-1 cells were seeded at a concen-
tration of 2U105/ml; 24 h later, various agents were
added to the medium, which was then incubated for
an additional 6 h or 24 h, or irradiated with 15 or 30
Gy of Q-rays, then incubated for an additional 6 h.
2.2. RNA extraction and Northern blot analysis
Total cellular RNA extraction and Northern blot
hybridization were performed as described previously
[31]. To extract polysomal RNA, cells were lysed in
0.5% Nonidet P-40, 1U1032 M Tris-HCl pH 7.4,
1.5U1031 M NaCl, 1.5U1033 M MgCl2, and
2U1032 M ribonucleoside vanadyl complexes
(R3380 Sigma) on ice for 30 min, then the nuclei
were precipitated with 3000 rpm (600Ug) for 10
min at 4‡C. The supernatant was centrifuged at
12 000 rpm (8000Ug) for 10 min at 4‡C to precipitate
the mitochondrial fraction and the resulting super-
natant was centrifuged at 60 000 rpm (105 000Ug)
at 4‡C for 60 min to pellet the microsome fraction.
RNA from the microsome fraction was used as poly-
somal RNA. RNAs were extracted from each cellu-
lar fraction by the guanidine method [35]. p21 cDNA
(provided by Dr. A. Noda, Meiji Cell Technology
Center, Japan), and L-actin DNA were digoxigenin-
labeled by the random primer method [35]. The hy-
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bridized probes were immunodetected with anti-di-
goxigenin antibody, then visualized with the colori-
metric substrates, 4-nitroblue tetrazolium chloride/5-
bromo-4-chloro-3-indolyl-phosphate (NBT/X-phos-
phate). The level of expression was normalized by
comparison with L-actin mRNA levels measured by
a densitometer.
2.3. Protein extraction and immunoblotting
Cells (1U107) were lysed in 1 ml of lyse bu¡er (1%
Nonidet P-40, 1U1032 M sodium phosphate pH 7.2,
1.5U1031 M NaCl, 1U1033 M EDTA, 5U1032 M
sodium £uoride, 1U1032 M sodium orthovanadate,
2 Wg/ml aprotinin, 2 Wg/ml leupeptin, and 5 Wg/ml
phenylmethylsulfonyl £uoride). After incubation on
ice for 30 min, the lysate was clari¢ed by ultracen-
trifugation at 30 000 rpm (30 000Ug) for 30 min at
4‡C. The cell lysate was immunoprecipitated with
anti-p21 polyclonal antibody (15431E PharMingen,
CA, USA) or anti-p21 monoclonal antibody (2G12,
PharMingen) with 0.01% SDS and 0.1% sodium de-
oxycholate, after which the precipitate was separated
by SDS-polyacrylamide gel electrophoresis and blot-
ted on a PVDF membrane (BioRad, CA, USA), then
incubated with anti-p21 monoclonal antibody (2G12
PharMingen), or anti-ubiquitin polyclonal anti-
body (N19 Santa Cruz, CA, USA). The blot was
washed to remove unbound antibody and incubated
with a biotinylated anti-mouse IgG for p21 detection
by monoclonal antibody or biotinylated anti-rabbit
IgG for the detection of ubiquitinated p21 by
polyclonal antibody. Following this incubation,
the membrane was again washed and incubated
with the streptoavidine-biotinylated alkaline phos-
phatase complex, which binds to the biotin of the
second antibody. After washing thoroughly, NBT/
X-phosphate substrate was used to visualize the
bands.
3. Results
3.1. p21 mRNA and protein product
In ML-1 cells, p21 mRNA expression increased
after 6 h treatment with 1U1035 M etoposide,
1U1035 M AraC, 1U1034 M DFO, and 1U1033
M hydroxyurea and also increased 6 h after treat-
ment with 15 Gy or 30 Gy Q-irradiation (Fig. 1).
To analyze p21 protein expression, we ¢rst per-
formed Western blot analysis for p21 protein using
cell lysates from 1U106 cells. The p21 band did not
appear with untreated and DFO-treated cells and
was faint in the cell lysate of etoposide-treated cells
(data not shown). Thus, to improve the sensitivity,
we concentrated the p21 protein from 1U107 cells by
immunoprecipitation with anti-p21 monoclonal anti-
body then performed Western blot analysis of the
precipitate. The p21 protein products were observed
only in cells treated with etoposide or Q-irradiation
(Fig. 2).
3.2. p21 mRNA in polysomal RNA
In order to examine whether or not p21 mRNAs
were properly translocated to the polysomes for
translation, polysomal RNA and nuclear RNA
were fractionated and analyzed by Northern blot-
ting. In polysomes, an enhanced level of p21
mRNA was detected after treatment with etoposide
or DFO, similar to that observed with total RNA
(Fig. 3). The p21 mRNAs were not detected in the
Fig. 1. p21 mRNA expression after treatment with various
agents. Total RNA was extracted from cells 6 h after 15 Gy
and 30 Gy Q-irradiation and the addition of 1U1035 M etopo-
side, 1U1034 M hydroxyurea, 1U1034 M DFO and 1U1035
M AraC. Twenty micrograms of total RNA were subjected to
electrophoresis on formaldehyde agarose gel, transferred to a
Hybond N membrane, and hybridized with digoxigenin-la-
beled probes. The level of expression was normalized by com-
parison with L-actin and indicated as relative intensity. UT,
untreated; 15 Gy, 15 Gy Q-irradiation; 30 Gy, 30 Gy
Q-irradiation; Etop, etoposide; HU, hydroxyurea; DFO, defer-
oxamine.
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supernatant after centrifugation at 60 000 rpm
(105 000Ug) (data not shown). These ¢ndings
strongly suggest post-transcriptional regulation of
p21 expression.
3.3. Proteasome inhibitor treatment
To analyze the association of degradation by pro-
teasome with the regulation of p21 expression, we
examined the e¡ect of the proteasome inhibitor, lac-
tacystin, at a concentration of 2U1036 M. First, the
p21 mRNA level was examined after treatment with
lactacystin. The level of p21 mRNA was slightly in-
creased after treatment with 2U1036 M lactacystin
for 6 h and 24 h (Fig. 4A). The level of p21 mRNA
was not a¡ected after treatment with DMSO used to
dissolve the lactacystin (Fig. 4A).
Fig. 4. E¡ect of proteasome inhibitor on p21 expression. (A) p21 mRNA. Total RNA was extracted from cells 6 h or 24 h after the
addition of 2U1036 M lactacystin or DMSO to dissolve the lactacystin. Twenty micrograms of total RNA were electrophoresed on
formaldehyde agarose gel, transferred to a Hybond N membrane, and hybridized with digoxigenin-labeled probes. The level of ex-
pression was normalized by comparison with L-actin and indicated as relative intensity. UT, untreated. (B) p21 protein product. Cells
were either untreated or treated with 1U1034 M DFO, 2U1036 M lactacystin, or both, and equal amounts of DMSO for dissolving
lactacystin for 24 h, or 1U1035 M etoposide for 6 h. ML-1 cell lysate was immunoprecipitated with anti-p21 monoclonal antibody
(2G12) and probed with anti-p21 monoclonal antibody (6G6). The p21 band is indicated. UT, untreated; Etop, etoposide; DFO, de-
feroxamine; Lac, lactacystin.
Fig. 3. p21 mRNA in the polysome fraction. ML-1 cells were
treated with 1U1035 M etoposide and 1U1034 M DFO for 6 h.
Total cellular RNA, nuclear RNA and polysomal RNA were
extracted separately and analyzed by Northern blot hybridiza-
tion. UT, untreated; DFO, deferoxamine; Etop, etoposide.
Fig. 2. Western blot analysis of p21 protein. ML-1 cells were
harvested 6 h after the addition of 1U1034 M DFO, 1U1035
M etoposide, 1U1035 M AraC and 1U1034 M hydroxyurea or
15 Gy Q-irradiation, then lysed with 1% Nonidet P-40. Cell ly-
sates were immunoprecipitated with anti-p21 monoclonal anti-
body (2G12) after treatment with 0.01% SDS and 0.1% sodium
deoxycholate, then electrophoresed on 10^20% SDS-PAGE. The
membranes were probed with anti-p21 monoclonal antibody
(6B6). UT, untreated; 15 Gy, 15 Gy Q-irradiation; DFO, defer-
oxamine; HU, hydroxyurea; Etop, etoposide; Lysate(3), im-
munoprecipitation was carried out using lyse bu¡er instead of
cell lysate.
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Next, we examined the expression of p21 protein
products by immunoblot analysis after immunopre-
cipitation of the cell lysate with anti-p21 monoclonal
antibody. Treatment with DFO for 6 h induced p21
mRNA, but not the p21 protein product (Fig. 2).
After incubation with lactacystin and DFO together
for 6 h, the p21 band did not appear (data not
shown). We therefore examined the p21 protein at
the other time point. After 24 h incubation with
DFO and lactacystin, the p21 band clearly appeared
(Fig. 4B). When ML-1 cells were incubated with lac-
tacystin alone, a weak p21 band was observed (Fig.
4B). This band may have been due to stabilization of
the p21 protein product and slight upregulation of
p21 mRNA expression at 24 h incubation.
Immunoblot analysis detected p21 protein prod-
ucts after treatment of ML-1 cells with lactacystin
and AraC or lactacystin and hydroxyurea (data not
shown).
We surmise that the p21 mRNA induced by DFO
treatment in ML-1 cells was utilized for transla-
tion.
3.4. Decrease in ubiquitination of p21 after treatment
with DNA damaging agents
Since the e¡ect of lactacystin became apparent
after 24 h treatment, we performed Western blot
analysis for the ubiquitinated p21 protein after 24
h incubation. The anti-ubiquitin polyclonal antibody
detected ubiquitinated p21 on the p21 immunopreci-
pitate as bands of approx. 30, 39 and 47 kDa respec-
tively in ML-1 cell lysate after treatment with DFO
and lactacystin (Fig. 5). These bands corresponded
to species of p21 conjugated with one, two or three
ubiquitin molecules (Mr 8600), respectively. These
bands were found to have the same size as those
detected by anti-p21 monoclonal antibody in cells
treated with DFO and lactacystin (Fig. 5, right pan-
el). By treatment with lactacystin alone, ubiquiti-
nated p21 bands were observed to a lesser extent.
The ubiquitinated p21 band was not detected in un-
treated, DFO, or etoposide-treated (6 h and 24 h)
cells.
4. Discussion
In this study, we analyzed the involvement of the
ubiquitin-proteasome degradation pathway in post-
transcriptional regulation of p21 expression.
The p21 mRNA induced in ML-1 cells after treat-
ment with DNA damaging agents, etoposide or
Q-irradiation, or non-DNA damaging agents, DFO
or hydroxyurea, were located in the polysome frac-
tion. However, the p21 protein product was observed
only after treatment with DNA damaging agents.
The discrepancy between the mRNA level and pro-
tein product level suggests that p21 expression is
post-transcriptionally regulated.
When ML-1 cells were treated with DFO and lac-
tacystin together, a high level of p21 protein product
was detected. The data showed that p21 mRNAs
induced by DFO treatment in ML-1 cells were trans-
lated e⁄ciently and the protein product remained
intact with the addition of proteasome inhibitor.
These results clearly suggested that the p21 product
is degraded by the ubiquitin-proteasome system, and
that the regulation of translational initiation of p21
mRNA is not likely to be a major regulatory mech-
anism in this case. Accordingly, these ¢ndings sug-
Fig. 5. Detection of the ubiquitinated p21 band. Cells were ei-
ther incubated with the proteasome inhibitor 2U1036 M lacta-
cystin for 24 h, 1U1034 M DFO for 24 h, or both, or 1U1035
M etoposide for 6 h and 24 h as indicated. Cell lysate was im-
munoprecipitated with anti-p21 monoclonal antibody (2G12),
and the immunoprecipitates were probed with anti-ubiquitin
polyclonal antibody (N19 Santa Cruz) (left). Cell lysate after
treatment with 2U1036 M lactacystin and 1U1034 M DFO for
24 h was immunoprecipitated with anti-p21 polyclonal antibody
(15431E), and probed with anti-p21 monoclonal antibody (6B6)
(right). Asterisks denote ubiquitinated p21 species. Arrows indi-
cate non-speci¢c bands. UT, untreated; Etop, etoposide; DFO,
deferoxamine; Lac, lactacystin; Lysate(3), immunoprecipitation
was carried out using lyse bu¡er instead of cell lysate.
BBAMCR 14362 8-9-98
K. Fukuchi et al. / Biochimica et Biophysica Acta 1404 (1998) 405^411 409
gested that p21 expression was regulated at the post-
transcriptional level.
Further detection of ubiquitinated p21 in ML-1
cells after treatment with proteasome inhibitors sup-
ports the notion that the ubiquitin-proteasome path-
way is involved in the regulation of p21 expression.
The p21 band observed on immunoblotting after
treatment with proteasome inhibitors had migrated
as unubiquitinated p21. There is some evidence that
the proteasome inhibitor, MG132, or lactacystin
treatment of cells increased the level of unubiquiti-
nated p53 [36,37]. Hence, we surmise that protea-
some inhibitor treatment, especially with lactacystin,
inhibits proteasome activity, and somehow inhibits
the ubiquitination of p21.
Ubiquitinated p21 bands were observed in cells
treated with proteasome inhibitors. Treatment with
the DNA damaging agent, etoposide, increased the
p21 mRNA and protein product, but the level of
ubiquitinated p21 diminished in ML-1 cells. This
suggested the existence of mechanisms for inhibiting
ubiquitin ligase activity or activation of deubiquiti-
nation by DNA damaging agents.
DNA damage regulates the cell cycle check point
through various mechanisms. DNA damage from
ionizing radiation activates the ATM gene product
to trigger the c-Abl tyrosine kinase activity independ-
ently from p53 status [38,39]. Ionizing radiation in-
duces the functional interaction between c-Abl kinase
and DNA-dependent protein kinase to associate
DNA double strand breaks [40]. Signal transduction
pathway is considered to convert DNA damage into
intracellular signals. Phosphorylation of target pro-
tein is reported to be a signal for ubiquitination in
the case of p27 [41], c-Jun [42], I-UB [43], and STAT-
1 [44]. In the future, we will examine the phosphor-
ylation of p21 after treatment with a DNA damaging
agent.
We concluded that (1) e⁄cient expression of p21
protein requires inhibition of the ubiquitin-protea-
some pathway, and (2) DNA damage inhibits the
ubiquitination of p21.
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